Purpose This review discusses the current state of prostate-specific membrane antigen
(PSMA)-based alpha therapy of metastatic castration-resistant prostate cancer (mCRPC) …

Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer
worldwide, with an estimated 2.3 million new cases (11.7%), followed by lung cancer …

Please see the Editorial Comment by Sungmin Woo discussing this article. BACKGROUND.
Bone scintigraphy (BS) using 99mTc-labeled methylene diphospho-nate (99mTc-MDP) …

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in
the majority of prostate cancer (PCa). PSMA has an enzymatic function that makes metabolic …

Calcium minerals such as hydroxyapatite (HAp) can be detected noninvasively in vivo using
nuclear imaging agents such as [18F] NaF (available from cyclotrons), for positron emission …

Objective: The aim of this study was to assess the diagnostic value of gallium-68-prostate
specific membra-8 ne antigen (6 Ga-PSMA) positron emission tomography/computed …

Monitoring therapy response in patients with metastatic castration-resistant prostate cancer
(mCRPC) treated with novel hormonal therapies, taxanes, and newly approved therapies is …

Imaging plays a vital role in detecting the recurrence of prostate cancer (PCa) to guide the
choice of salvage therapy. Gallium-68 prostate-specific membrane antigen positron …

Prostate specific membrane antigen positron emission tomography (PSMA PET) is an
excellent molecular imaging technique for prostate cancer. Currently, PSMA PET for patients …

Prostate-specific membrane antigen (PSMA) is an ideal target for the diagnosis and
treatment of prostate cancer. Due to the short half-life in blood, small molecules/peptides are …